AUPH - Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
2025-08-06 18:02:37 ET
In early to mid-2024, it appeared sales of Aurinia Pharmaceuticals Inc.'s ( AUPH ) Lupkynis might have topped out, and the stock was at lows below $5. When Q1 '24 earnings confirmed a resumption of sales growth in May 2024, I switched from Hold to a Buy , and the name is up about 117% since that article. I've continued to rate the name a Buy along the way, most recently in April 2025, anticipating sales of Lupkynis to continue to increase....
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)